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Objectives High blood pressure (BP) is associated with
diastolic dysfunction, but the consequence of elevated
BP over the adult life course on diastolic function is
unknown. We hypothesised that high BP in earlier
adulthood would be associated with impaired diastolic
function independent of current BP.
Methods Participants in the Medical Research Council
National Survey of Health and Development birth cohort
(n=1653) underwent investigations including
echocardiography at age 60–64 years. The relationships
between adult BP, antihypertensive treatment (HTT) and
echocardiographic measures of diastolic function were
assessed using adjusted regression models.
Results Increased systolic BP (SBP) at ages 36, 43 and
53 years was predictive of increased E/e0 and increased
left atrial volume. These effects were only partially
explained by SBP at 60–64 years and increased left
ventricular mass. HTT was also associated with poorer
diastolic function after adjustment for SBP at
60–64 years. Faster rates of increase in SBP in midlife
were also associated with increased poorer diastolic
function.
Conclusions High SBP in midlife is associated with
poorer diastolic function at age 60–64 years. Early
identiﬁcation of individuals with high BP or rapid rises in
BP may be important for prevention of impaired cardiac
function in later life.
INTRODUCTION
With an ageing population, and better postmyocar-
dial infarction survival, the burden of congestive
heart failure is increasing and represents a major
public health challenge.1 Diastolic dysfunction is
common in people over 45 years with a prevalence
of 28% in a large community study,1 and is a pre-
cursor of heart failure with preserved ejection frac-
tion (HFPEF).2 Echocardiographic measures of
diastolic dysfunction and elevated left ventricular
(LV) ﬁlling pressure also predict a threefold
increased cardiac mortality and a twofold increased
all-cause mortality in those with normal ejection
fractions.2 3 High systolic blood pressure (SBP) is
an important cause of diastolic dysfunction, and
there is evidence that raised antecedent SBP in
early and midadulthood is associated with increased
risk of heart failure,4 and elevated risk of cardiovas-
cular mortality independent of current blood pres-
sure (BP).5 However, there has been limited work
investigating the effects of longitudinal changes in
BP over adulthood on diastolic function.6 We have
previously shown that increased SBP in adult
midlife is associated with increased LV mass in later
life independent of later SBP and that rapid rises in
midlife SBP might play a key role.7 We hypothe-
sised that a similar relationships may exist between
SBP and diastolic function and also aimed to deter-
mine the extent to which this might be due to
increased LV mass. In addition, we examined the
association between antihypertensive treatment
(HTT) and subsequent diastolic function.
METHODS
Study patients
The UK Medical Research Council National Survey
of Health and Development (MRC NSHD) is a
prospective birth cohort study of singleton births
that occurred in 1 week of March 1946 in England,
Scotland and Wales (5362 births; 2547 women,
2815 men). Follow-up has included over 20 con-
tacts with the whole cohort between birth and the
most recent data collection when the participants
were between 60 and 64 years of age.7
Study members still alive and with a known
current address in England, Scotland or Wales were
invited for an assessment at one of six clinical
research facilities (CRFs) or to be visited by a
research nurse at home. Invitations were not sent
to those who had died (N=778), who were living
abroad (N=570), had previously withdrawn from
the study (N=594) or had been lost to follow-up
(N=564). Of the 2856 invited participants, 2229
(78%) were assessed: 1690 (59%) attended a CRF
and the remaining 539 were visited at home.
Echocardiography was only carried out at the CRF
(N=1653). The participating sample remains
broadly representative of native born British men
and women of the same age.8
Ethical approval was obtained from the Central
Manchester Research Ethics Committee (07/
H1008/168) and the Scotland A Research Ethics
Committee. Written informed consent was
obtained from each study member at each stage of
data collection.
Anthropometry and BP measurement
Height and weight were measured at the clinic visit
and body mass index (BMI) calculated. Sitting bra-
chial BP was measured in the upper right arm with
an appropriately sized cuff after 5 min of rest at
53 years and 60–64 years with the second
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measurement used in analyses, or the ﬁrst measure where the
second was missing. A Hawksley random zero sphygmomanom-
eter (Hawksley & Sons, Lancin, UK; a state of the art machine
at the time) was used at 36 and 43 years.5 9 A validated oscillo-
metric device (Omron HEM-705) was used in later in home
visits. To enable comparison of BP measured by the different
machines, the measurements from the random zero sphygmo-
manometer were adjusted using published conversion
equations.10
Antihypertensive treatment and diabetes status
Prior to clinic attendance, study members completed a postal
questionnaire that included details of current medication.
Antihypertensive medications for the last two rounds were clas-
siﬁed according to International Classiﬁcation of Diseases and
related Health Problems classiﬁcation.11 Self-reported and
doctor diagnosed type 2 diabetes mellitus (T2DM) was obtained
from the postal questionnaires and reports at earlier follow-ups.
Echocardiography
Of the 1690 participants who attended a clinic, 1653 (798 men
and 855 women, mean age 63.3±1.1 years (1SD)) underwent
echocardiography using GE Vivid I machines (GE, Connecticut,
USA) and 1576 had at least one analysable image (95%).
Echocardiographic images were obtained from parasternal long
axis and short axis, apical ﬁve-chamber, four-chamber, three-
chamber, two-chamber and aortic views along with conventional
and tissue Doppler in the four-chamber view. Image analysis
was carried out by three experienced British Society of
Echocardiography-accredited readers including the author
(AKG) masked to patient identity using GE EchoPac software.
The following markers of diastolic function were measured in
accordance with American Society of Echocardiography/
European Association of Echocardiography recommendations—
ratio of early (E) to late (A) transmitral Doppler ﬂow (E/A),
early (e0) myocardial velocity at the mitral valve annulus
(average of septal and lateral wall measures) e0, E/e0 and ratio of
early and late (a0) myocardial velocities at the mitral valve
annulus (average of septal and lateral wall measures) e0/a0.12 E/e0
was calculated as an estimate of LV ﬁlling pressure.12 Left atrial
volume indexed to body surface area (LAVI) was also examined
as a marker of chronically elevated LV ﬁlling pressures.13
Quality control measures included standardised training for
senior, experienced echocardiographers and readers, echocardio-
grapher observation by trained echocardiographers, periodic
reader and echocardiographer review and refresher sessions,
phantom studies on ultrasound machines and continuous quality
control audit throughout the period of data collection. Blind
duplicate reading reproducibility studies (n=70 on two occasions)
were carried out to establish inter-reader and intrareader variabil-
ity. These showed excellent reproducibility (intraclass correlation
coefﬁcients were >0.90 for most measurements).
Statistical analysis
Statistical analysis was performed using Stata V.14.1 (StataCorp
LP, USA). Initially, separate regression models investigated the
association between SBP at each of the 4 ages at which it was
measured and measures of diastolic function at 60–64 years,
with adjustment for sex, age at clinic visit and clinic attended.
We examined whether associations were linear by inspection of
residuals. Given evidence that cardiac function may differ by
sex,1 we also investigated whether associations with SBP were
subject to effect modiﬁcation by sex through inclusion of a
sex×SBP term in models, but this was not statistically signiﬁcant
in any model. Consequently, we show data from models includ-
ing both sexes that were adjusted for sex. HTT at the same age
as BP measurement was then added to the models. Additional
models assessed whether earlier SBP remained predictive once
current SBP was also included, that is, to what extent antecedent
SBP was independent of current SBP. This is an important con-
sideration given the anticipated correlations between SBP at dif-
ferent times within an individual (tracking). Further statistical
models were constructed by including potential confounders
BMI, T2DM, smoking and physical activity status at age 60–64
years. In a further model left ventricular mass indexed to body
surface area (LVMI) was included with possible confounders to
explore the extent to which LVMI might mediate the associa-
tions observed.
In order to maintain the sample size and minimise bias intro-
duced by missing data in fully adjusted analyses, we employed a
multiple imputation procedure to impute missing covariates. For
each outcome, a total of 20 imputed datasets were obtained
using chained equations implemented using imputation by
chained equations in Stata. For the imputation models we
included all variables in the ﬁnal adjusted analytic model, each
model, as well as the outcome and additional variables that
helped predict the missing covariates. The regression coefﬁcients
and standard errors were calculated for each imputed dataset,
and then combined using Rubin’s rule.
To investigate whether rate of change in SBP at a particular
period of midlife was more strongly associated with diastolic
function, we calculated the change in SBP for the periods 36–43
years, 43–53 years and 53–60/64 years conditional on earlier
SBP by modelling each SBP measure (from age 43 years) on the
earlier measure(s) for each sex and saving the residuals. These
residuals reﬂect SBP velocity and can be interpreted as the
change in SBP in an individual above or below that expected on
average in the sample given their earlier SBP.14 The residuals
were standardised (mean=0 and SD=1) to allow a comparison
of the relative strength of associations between periods. We sub-
sequently ﬁtted regression models including all these standar-
dised changes with each of the measures of diastolic function as
the outcome. This analysis was performed only for individuals
who had all variables observed (complete case analysis). Two
models were constructed: model 1—adjusted for age, sex and
CRF attended; model 2—model 1+T2DM+BMI+smoking
status+physical activity status+current HTT. p Values were cal-
culated using Wald tests. Similar analyses were repeated for dia-
stolic BP (DBP), pulse pressure (PP) and mean arterial pressure
(MAP).
Sensitivity analyses were carried out to assess whether the
associations with SBP remained unchanged if those who were
hypertensive (SBP≥140 mm Hg or DBP≥90 mm Hg) were
excluded.
RESULTS
Characteristics of participants with any echocardiography data
at age 60–64 years are shown in table 1. Those with unanalys-
able echocardiograms had higher BMIs and heart rates, but BP
did not differ.7 Additional participant characteristics are pre-
sented in online supplementary table S1.
SBP from age 53 years was negatively associated with e0
(table 2). This relationship weakened with progressive risk
factor adjustment. HTTwas negatively associated with e0 in the
minimally adjusted model from age 53 years.
Broadly similar ﬁndings were observed when the associations
between current and antecedent SBP and E/A were examined,
although relationships tended to be weaker. SBP at 53 and
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60–64 years was predictive of E/A and HTT at any age was
unrelated to E/A (table 3). Data relating SBP measured at
various ages to e0/a0 were consistent with observations for e0 and
E/A (data not shown).
SBP from 36 years onwards was positively associated with
increased E/e0 (table 4). The relationship persisted after adjust-
ment for age, sex, clinic attended, current HTT/SBP/BMI/
T2DM/smoking/physical activity. SBP at age 53 years and HTT
at age 53 years were also positively associated with LAVI
(table 5). Analyses were repeated replacing SBP with DBP, PP or
MAP should similar associations (data not shown).
From 43 years onwards, those on HTT had increased E/e0;
this was not affected substantively by adjustment for current
SBP; regression coefﬁcients were slightly attenuated by adjust-
ment for BMI/T2DM/smoking/physical activity although rela-
tionships remained statistically signiﬁcant (table 4). We also
investigated whether the effect of earlier SBP was mediated via
LV hypertrophy by inclusion of LVMI into regression models.
This was not the case.
We investigated whether relationships between elevated BP in
earlier life and e0 and E/e0 might be driven by inclusion of
people who went on to develop hypertension. However, when
those who were hypertensive at 60–64 years (SBP ≥140 mm Hg
or DBP ≥90 mm Hg) were excluded from the analysis, the asso-
ciations remained very similar (data not shown).
We looked to see whether there was a sensitive period when
rate of change in SBP had most inﬂuence on diastolic function
and ﬁlling pressure. Increased rates of rise in SBP over the age
periods 43–53 and 53–60/64 years were also signiﬁcantly
associated with worse e0 (ﬁgure 1A) and E/A (ﬁgure 1B).
Increased rate of rise in SBP at all age periods (36–43 years,
43–53 years and 53–60/64 years) was associated with increased
E/e0 (ﬁgure 1C), although the relationship was strongest over
the period 43–53 years in the minimally adjusted model. The
rate of rise in the 43–53 years period was also associated with
increased LAVI (ﬁgure 1D).
DISCUSSION
BP from early midlife predicted worse diastolic function and
evidence of elevated ﬁlling pressure at age 60–64 years. This
effect was independent of current BP, extended across the
whole range of BP, and was not limited to people with hyper-
tension or those who went on to develop hypertension at the
time when diastolic function was assessed. We observed that
those on HTT from early midlife had poorer diastolic function
than those not on HTT even after current BP was accounted
for. Further, we found that individuals showing comparatively
rapid rises in SBP between 43–53 years and 53–60/64 years
had worse subsequent diastolic function irrespective of their
absolute level of SBP. Since the rise in BP in the UK population
typically begins to accelerate around the fourth decade of life
until it slows again in later life,15 we suggest that the period
40–60 years may represent a sensitive period when an acceler-
ated rise in BP adversely inﬂuences future development of dia-
stolic dysfunction.
There has been limited work in the past on relating ante-
cedent BP with future diastolic function. Arnlöv et al reported
that higher SBP and DBP at the age of 50 years were associated
Table 1 Echocardiographic and cardiac risk factor characteristics of study participants
All Men Women
Variable (at age 60–64 years unless stated otherwise) n Result n Result n Result
Age, years 1626 63.2 (1.1) 786 63.2 (1.2) 840 63.3 (1.1)
BMI, kg/m2 1633 27.7 (4.6) 791 27.7 (4.0) 842 27.6 (5.2)
SBP, mm Hg 1633 135.7 (18.0) 791 139.0 (17.8) 842 132.7 (17.6)
SBP in those on HTT, mm Hg 347 137.4 (17.4) 179 138.2 (16.2) 168 131.8 (16.9)
SBP in those not on HTT, mm Hg 1120 134.9 (18.0) 518 136.1 (17.6) 602 129.9 (15.8)
SBP in those with unknown HTT status, mm Hg 166 137.4 (18.6) 92 138.1 (17.3) 74 132.1 (17.2)
SBP at age 53 years, mm Hg 1537 134.3 (19.1) 738 138.0 (18.9) 799 130.8 (18.5)
SBP at age 43 years, mm Hg 1522 123.7 (14.1) 735 128.1 (13.1) 787 119.6 (13.6)
SBP at age 36 years, mm Hg 1479 120.0 (13.7) 714 125.8 (12.8) 765 114.6 (12.3)
DBP, mm Hg 1633 77.3 (9.7) 791 79.0 (9.8) 842 75.7 (9.3)
DBP at age 53 years, mm Hg 1537 83.5 (11.9) 738 86.4 (11.9) 799 80.9 (11.2)
DBP at age 43 years, mm Hg 1522 80.5 (9.5) 735 83.4 (9.0) 787 77.8 (9.1)
DBP at age 36 years, mm Hg 1477 78.3 (9.6) 713 80.8 (9.4) 764 75.9 (9.3)
Heart rate, bpm 1630 68.9 (11.2) 789 67.4 (11.3) 841 70.3 (10.9)
IVSD, cm 1473 1.1 (0.2) 701 1.1 (0.2) 772 1.0 (0.2)
PWT, cm 1471 1.0 (0.2) 699 1.1 (0.2) 772 0.9 (0.2)
RWT 1469 0.4 (0.1) 699 0.4 (0.1) 770 0.4 (0.1)
LVM, g 1471 181.3 (59.3) 699 209.3 (60.3) 772 156.0 (45.4)
LVMI, g/m2 1471 95.7 (26.6) 699 104.1 (27.9) 772 88.1 (22.8)
Ejection fraction (%) 1459 68.7 (9.7) 692 67.2 (10.1) 767 69.9 (9.2)
E/A 1576 1.0 (0.3) 755 1.0 (0.3) 821 1.0 (0.3)
e0, cm/s 1533 8.8 (1.9) 727 8.9 (1.9) 806 8.8 (1.9)
E/e0 1490 7.9 (2.1) 701 7.5 (2.0) 789 8.3 (2.1)
e0/a0 1507 0.8 (0.2) 709 0.8 (0.2) 798 0.9 (0.2)
LAVI, mL/m2 1417 21.1 (7.2) 701 22.0 (7.4) 716 20.2 (7.0)
Data are mean (SD), median (interquartile range) or n (%) as appropriate.
BMI, body mass index; DBP, diastolic blood pressure; IVSD, interventricular septal thickness in diastole; LAVI, left atrial volume indexed to body surface area; LVM, left ventricular mass;
LVMI, left ventricular mass indexed to body surface area; PWT, left ventricular posterior wall thickness in diastole; RWT, relative wall thickness; SBP, systolic blood pressure.
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Table 2 Regression between e0 at 60–64 years and SBP and antihypertensive treatment at four time points with further adjustment for covariables
Independent variable
Model 1 Model 2 Model 3 Model 4 Model 5
β (95% CI) p Value β (95% CI) p Value β (95% CI) p Value β (95% CI) p Value β (95% CI) p Value
Age 36 (n=1533) SBP −0.006 (−0.014 to 0.002) 0.125 −0.006 (−0.014 to 0.002) 0.122 −0.001 (−0.009 to 0.007) 0.855 −0.002 (−0.010 to 0.006) 0.619 0.000 (−0.008 to 0.008) 0.931
Age 43 (n=1533) SBP −0.006 (−0.013 to 0.002) 0.128 −0.005 (−0.012 to 0.002) 0.171 0.002 (−0.067 to 0.010) 0.598 0.001 (−0.007 to 0.008) 0.816 0.000 (−0.009 to 0.008) 0.959
Age 53 (n=1533) SBP −0.011 (−0.017 to −0.006) <0.001 −0.010 (−0.016 to −0.005) <0.001 −0.005 (−0.011 to 0.001) 0.084 −0.004 (−0.010 to 0.002) 0.157 −0.002 (−0.006 to 0.009) 0.694
Age 60–64 (n=1533) SBP −0.017 (−0.022 to −0.012) <0.001 −0.017 (−0.022 to −0.011) <0.001 NR NR −0.015 (−0.020 to −0.009) <0.001 −0.014 (−0.019 to −0.008) <0.001
Age 36 HTT NR NR 0.112 (−0.846 to 1.070) 0.819 0.018 (−0.937 to 0.973) 0.971 0.039 (−0.910 to 0.989) 0.935 −0.110 (−1.157 to 0.937) 0.837
Age 43 HTT NR NR −0.619 (−1.296 to 0.058) 0.073 −0.598 (−1.271 to 0.075) 0.081 −0.495 (−1.163 to 0.173) 0.146 −0.403 (−1.064 to 0.257) 0.231
Age 53 HTT NR NR −0.333 (−0.635 to− 0.032) 0.030 −0.331 (−0.630 to −0.032) 0.030 −0.296 (−0.598 to 0.006) 0.054 −0.230 (−0.533 to 0.073) 0.136
Age 60–64 HTT NR NR −0.253 (−0.490 to −0.016) 0.036 NR NR −0.162 (−0.407 to 0.082) 0.192 −0.094 (−0.340 to 0.152) 0.453
Imputed (n=1533 for all models—with valid outcome and SBP at age 60–64 years). The variable β is regression coefficient for e0 versus SBP (mm Hg) or antihypertensive treatment (HTT). Model 1: adjusted for age sex and CRF attended. Model 2: model 1
+antihypertensive treatment (HTT) at given age (for SBP) or model 1+SBP at given age (for HTT). Model 3: model 2+SBP at 60–64 years. Model 4: model 3+T2DM+BMI+smoking status+physical activity status. Model 5: model 4+left ventricular mass
indexed to body surface area. Numbers of individuals receiving HTT were 51 (2%), 107 (3%), 438 (15%) and 640 (27%) at age 36, 43, 53 and 60–64 years, respectively.
BMI, body mass index; CRF, clinical research facility; NR, not relevant; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus.
Table 3 Regression between E/A at 60–64 years and SBP and antihypertensive treatment at four time points with further adjustment for covariables
Independent variable
Model 1 Model 2 Model 3 Model 4 Model 5
β (95% CI)×10−3 p Value β (95% CI)×10−3 p Value β (95% CI)×10−3 p Value β (95% CI)×10−3 p Value β (95% CI)×10−3 p Value
Age 36 (n=1576) SBP 0.3 (−0.8 to 1.5) 0.564 0.3 (−0.8 to 1.4) 0.598 0.9 (−0.2 to 2.1) 0.116 0.8 (−0.4 to 1.9) 0.190 0.8 (−0.3 to 2.0) 0.170
Age 43 (n=1576) SBP 0.4 (−0.7 to 1.4) 0.481 0.4 (−0.6 to 1.5) 0.443 1.3 (0.2 to 2.3) 0.024 1.1 (0.06 to 2.2) 0.039 1.2 (0.1 to 2.2) 0.036
Age 53 (n=1576) SBP −1.4 (−2.2 to −0.7) <0.001 −1.5 (−2.3 to −0.7) <0.001 −1.0 (−1.8 to −0.1) 0.025 −0.7 (−1.5 to 0.1) 0.099 −0.7 (−1.5 to 0.2) 0.118
Age 60–64 (n=1576) SBP −1.8 (−2.6 to −1.1) <0.001 −1.8 (−2.6 to −1.0) <0.001 NR NR −1.5 (−2.2 to −0.7) <0.001 −1.4 (−2.2 to −0.7) <0.001
Age 36 HTT NR NR 70 (−80 to 220) 0.356 59 (−89 to 207) 0.430 70 (−73 to 214) 0.338 70 (−74 to 241) 0.339
Age 43 HTT NR NR −35 (−131 to 62) 0.443 −36 (−133 to 61) 0.464 −27 (−131 to 77) 0.613 −17 (−127 to 93) 0.761
Age 53 HTT NR NR 27 (−16 to 70) 0.221 25 (−18 to 69) 0.248 40 (−3 to 83) 0.067 42 (−2 to 85) 0.059
Age 60–64 HTT NR NR −25 (−58 to 9) 0.149 NR NR 1.4 (−33 to 35) 0.936 2.9 (−32 to 37) 0.871
Imputed (n=1576 for all models—with valid outcome and SBP at age 60–64 years). The variable β is regression coefficient for E/A versus SBP (mm Hg) or antihypertensive treatment (HTT). Model 1: adjusted for age sex and CRF attended. Model 2: model
1+HTT at given age (for SBP) or model 1+SBP at given age (for HTT). Model 3: model 2+SBP at 60–64 years. Model 4: model 3+T2DM+BMI+smoking status+physical activity status. Model 5: model 4+left ventricular mass indexed to body surface area.
Numbers of individuals receiving HTT were 51 (2%), 107 (3%), 438 (15%) and 640 (27%) at age 36, 43, 53 and 60–64 years, respectively.





















Table 4 Regression between E/e0 at 60–64 years and SBP and antihypertensive treatment at four time points with further adjustment for covariables (n=1490 for all models—with valid outcome and
SBP at age 60–64 years)
Independent variable
Model 1 Model 2 Model 3 Model 4 Model 5
β (95% CI) p Value β (95% CI) p Value β (95% CI) p Value β (95% CI) p Value β (95% CI) p Value
Age 36 (n=1490) SBP 0.015 (0.006 to 0.024) 0.001 0.015 (0.006 to 0.024) 0.001 0.007 (−0.002 to 0.016) 0.118 0.008 − (0.001 to 0.017) 0.072 0.006 (−0.003 to 0.015) 0.170
Age 43 (n=1490) SBP 0.019 (0.011 to 0.027) <0.001 0.017 (0.009 to 0.025) <0.001 0.008 (0.000 to 0.017) 0.052 0.009 (0.001 to 0.017) 0.031 0.009 (0.000 to 0.017) 0.045
Age 53 (n=1490) SBP 0.022 (0.017 to 0.028) <0.001 0.020 (0.014 to 0.026) <0.001 0.013 (0.007 to 0.019) <0.001 0.011 (0.003 to 0.017) 0.001 0.010 (0.003 to 0.016) 0.003
Age 60–64 (n=1490) SBP 0.024 (0.019 to 0.030) <0.001 0.023 (0.018 to 0.029) <0.001 NR NR 0.021 (0.015 to 0.027) <0.001 0.020 (0.014 to 0.025) <0.001
Age 36 HTT NR NR −0.06 (−1.18 to 1.06) 0.917 0.06 (−1.05 to 1.18) 0.909 0.004 (−1.08 to 1.09) 0.994 0.01 (−1.06 to 1.08) 0.981
Age 43 HTT NR NR 1.38 (0.62 to 2.13) <0.001 1.34 (0.59 to 2.08) <0.001 1.13 (0.39 to 1.87) 0.003 1.03 (0.30 to 1.75) 0.006
Age 53 HTT NR NR 0.72 (0.39 to 1.05) <0.001 0.72 (0.39 to 1.04) <0.001 0.62 (0.30 to 0.95) <0.001 0.55 (0.23 to 0.88) 0.001
Age 60–64 HTT NR NR 0.69 (0.44 to 0.95) <0.001 NR NR 0.55 (0.29 to 0.82) <0.001 0.48 (0.21 to 0.75) <0.001
The variable β is regression coefficient for E/e0 versus SBP (mm Hg) or antihypertensive treatment (HTT). Model 1: adjusted for age sex and CRF attended. Model 2: model 1+HTT at given age (for SBP) or model 1+SBP at given age (for HTT). Model 3:
model 2+SBP at 60–64 years. Model 4: model 3+T2DM+BMI+smoking status+physical activity status. Model 5: model 4+left ventricular mass indexed to body surface area. Numbers of individuals receiving HTT were 51 (2%), 107 (3%), 438 (15%) and
640 (27%) at age 36, 43, 53 and 60–64 years, respectively.
BMI, body mass index; CRF, clinical research facility; NR, not relevant; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus.
Table 5 Regression between LAVI at 60–64 years and SBP and antihypertensive treatment at four time points with further adjustment for covariables (n=1417 for all models—with valid outcome
and SBP at age 60–64 years)
Independent variable
Model 1 Model 2 Model 3 Model 4 Model 5
β (95% CI) p Value β (95% CI) p Value β (95% CI) p Value β (95% CI) p Value β (95% CI) p Value
Age 36 (n=1417) SBP 0.042 (0.013 to 0.072) 0.005 0.041 (0.012 to 0.071) 0.006 0.035 (0.004 to 0.065) 0.025 0.38 (0.008 to 0.068) 0.014 0.024 (−0.005 to 0.053) 0.103
Age 43 (n=1417) SBP 0.042 (0.013 to 0.070) 0.004 0.040 (0.011 to 0.069) 0.006 0.021 (0.001 to 0.061) 0.042 0.035 (0.005 to 0.064) 0.021 0.026 (−0.003 to 0.055) 0.079
Age 53 (n=1417) SBP 0.056 (0.036 to 0.075) <0.001 0.047 (0.027 to 0.068) <0.001 0.043 (0.021 to 0.065) <0.001 0.038 (0.016 to 0.060) 0.001 0.023 (0.023 to 0.045) 0.035
Age 60–64 (n=1417) SBP 0.030 (0.009 to 0.051) 0.004 0.028 (0.008 to 0.050) 0.007 NR NR 0.020 (−0.013 to 0.041) 0.066 −0.001 (−0.023 to 0.022) 0.944
Age 36 HTT NR NR 2.560 (−1.650 to 6.771) 0.232 2.769 (−1.433 to 6.971) 0.195 1.931 (−2.262 to 6.124) 0.365 2.022 (−1.935 to 5.979) 0.315
Age 43 HTT NR NR 2.179 (−0.393 to 4.751) 0.097 2.205 (−0.352 to 4.762) 0.091 1.388 (−1.204 to 3.981) 0.293 0.657 (−1.826 to 3.141) 0.603
Age 53 HTT NR NR 2.304 (1.139 to 3.469) <0.001 2.326 (1.161 to 3.491) <0.001 1.979 (0.799 to 3.159) 0.001 1.418 (0.260 to 2.576) 0.016
Age 60–64 HTT NR NR 1.290 (0.667 to 2.512) 0.001 – NR 1.084 (0.134 to 2.033) 0.025 0.6453 (−0.466 to 1.371) 0.334
The variable β is regression coefficient for LAVI versus SBP (mm Hg) or antihypertensive treatment (HTT). Model 1: adjusted for age sex and CRF attended. Model 2: model 1+HTT at given age (for SBP) or model 1+SBP at given age (for HTT). Model 3:
model 2+SBP at 60–64 years. Model 4: model 3+diabetes mellitus+body mass index+smoking status+physical activity status. Model 5: model 4+left ventricular mass indexed to body surface area. Numbers of individuals receiving HTT were 51 (2%), 107
(3%), 438 (15%) and 640 (27%) at age 36, 43, 53 and 60–64 years, respectively.





















with decreased E/A measured 20 years later in the Swedish
Uppsala cohort.16 Hypertension is thought to cause diastolic
dysfunction via impaired LV relaxation and reduced LV compli-
ance.17 Ultimately, the elevated ﬁlling pressures associated with
severe diastolic dysfunction can lead to HFPEF18 or pulmonary
oedema.19 Interestingly, Lee et al reported that higher BP and
BMI in midlife were predictive of incident heart failure in later
life in the Framingham study.4 Our data suggest that this
relationship may be mediated at least in part via diastolic
dysfunction.
Randomised clinical trials such as Antihypertensive and Lipid
Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
and HYpertension in the Very Elderly Trial (HYVET) have
demonstrated the beneﬁts of treating hypertension in terms of
decreased incidence of new heart failure and heart failure
admissions.20 However, optimal management of diastolic dys-
function remains unclear: trials in HFPEF have demonstrated
little or no beneﬁt with conventional heart failure medication.21
There is evidence for improvement in diastolic function with
short-term HTT,22 23 but longer-term HTT was not associated
with improvement of diastolic function despite regression of LV
mass in a substudy of the Anglo Scandinavian Cardiac Outcomes
trial.24 Nevertheless, BP control is considered a cornerstone of
management of these patients.25 In our cohort we found that from
43 years onwards, for any given level of BP (including for BP in
the normal range, those on HTT had worse diastolic function at
60–64 years than those not on HTT). These data should not be
interpreted as indicating that antihypertensive therapy has a nega-
tive effect on diastolic function, the observational design of the
study precludes any such interpretation. Possible explanations of
this ﬁnding include: inadequate long-term control of BP despite
treatment26 27—it should be noted that only approximately half of
hypertensive participants were controlled to <140/90 mmHg at
age 60–64 years; or the accrual of some BP—related damage
prior to initiation of treatment. If the latter were true, individuals
at risk may need to be treated at an earlier age and/or to lower
target BP.
Elevated antecedent BP is associated with LV hypertrophy,7
and this could contribute to impaired diastolic function;
however, adjustment for LVMI only moderately attenuated asso-
ciations between antecedent BP and diastolic function and it
seems that associations, particularly for E/e0 and LAVI, are inde-
pendent of increased LVMI. Some cross-sectional studies have
found PP to be the best predictor of diastolic function,28 29 but
we found relatively similar associations between antecedent SBP,
DBP, PP and MAP and diastolic function.
Figure 1 Association between standardised residuals of change in systolic blood pressure (SBP) over three time periods (36–43 years),
(43–53 years) and (53–60 to 64 years) conditional on the earlier measure(s) and markers of diastolic function at age 60–64 years. The residuals can
be interpreted as the standardised rate of change in SBP in an individual above or below that expected on average in the sample given their earlier
SBP. (A) e0 at age 60–64 years (n=1172). (B) E/A at age 60–64 years (n=1190). (C) E/e0 at age 60–64 years (n=1120). (D) Left atrial volume indexed
to body surface area at age 60–64 years (n=1054). Data points are β coefﬁcients and the bars represent 95% CIs. Model 1 (•): adjusted for age, sex
and clinical research facility attended. Model 2 (○): model 1+diabetes mellitus+body mass index+smoking status+physical activity status+current
antihypertensive treatment. p Values were calculated using Wald tests and p<0.05 indicates a signiﬁcant association between the rate of change in
SBP in the speciﬁed period and the measure of diastolic function.
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Strengths and limitations
Our ﬁndings are derived from a nationally representative sample
of native-born British people born in 1946.8 Using the life course
approach in relating BP at different ages and change in BP over
time to future diastolic function is unique and is a major strength
of our study. This was only possible due to detailed repeated
measurements of risk factors and recording of HTT in our study,
which is the longest running birth cohort in the UK. Studies of
birth cohorts have a number of advantages, notably that account-
ing for the effect of age is much less problematic. We used tissue
Doppler as our primary measure of diastolic function, this has
the advantage that it can distinguish normal diastolic function
from pseudonormalisation.30 Pseudonormalisation will tend to
attenuate relationships between antecedent BP and diastolic func-
tion assessed by E/A, and probably accounts for the generally
weaker relationships seen using this measure of diastolic func-
tion. Missing data are inevitable in studies as long-running as the
MRC NSHD (>60 years), although participant retention was
good in comparison with other cohorts.11 Compared with those
study members who attended clinic for clinical examination and
echocardiography, those who only had clinical examinations at
home visits had higher BMI and heart rates. However, participa-
tion of relatively more healthy individuals in the echocardiog-
raphy study is, if anything, likely to have weakened relationships
between BP and diastolic function. There were no measurements
of BP prior to 36 years, and hence we cannot comment on the
importance of BP in earlier life periods. We are limited to identi-
fying a sensitive period from three intervals as the study has only
four measures of BP. This lack of BP measurements in limits our
ability to determine whether BP control was optimal between
measurements. Echocardiography was only carried out in the last
round of data collection; hence the possibility of diastolic dys-
function preceding the rise in BP cannot be excluded, although
such a relationship seems unlikely.
CONCLUSIONS
BP from the age of 36 years predicts diastolic function in people
aged 60–64 years independently of current BP (for E/e0 and
LAVI); faster increases in BP in midlife are particularly detri-
mental. People on HTT have more adverse diastolic function
even when current BP is taken into account suggesting that early
risk factor modiﬁcation may be important to prevent the
adverse effects of BP on diastolic function.
Key messages
What is already known on this subject?
▸ High blood pressure (BP) is associated with diastolic
dysfunction in cross-sectional studies.
▸ Very little is known about the longitudinal effects of high BP
and changes in BP over adult life on future diastolic function.
What might this study add?
▸ High blood pressure (BP) levels, and rises in BP in midadult
life adversely affect diastolic function up to 28 years later.
▸ Hypertensive individuals have worse diastolic function even
when their current BP was taken into account.
How might this impact on clinical practice?
▸ Early identiﬁcation of those with fast rising blood pressure
(BP) (even in the ‘normal’ BP range) may be important to
prevent diastolic dysfunction in later life.
Acknowledgements We thank the NSHD study members who took part in the
clinic data collection for their continuing support. We thank members of the NSHD
scientiﬁc and data collection teams at the MRC Unit for Lifelong Health and Ageing
at UCL and the six Clinical Research Facilities.
Contributors AKG, RH and ADH conceived and designed the research and carried
out the statistical analyses. DK secured funding for the study. All authors critically
reviewed the manuscript. AKG, ADH and RH are responsible as guarantors for the
overall content.
Funding The authors are/were employees of one of the following organisations:
Barts Health NHS Trust, University College London or Imperial College. DF, ADH and
JM received support from the Imperial College Academic Health Sciences Biomedical
Research Centre. NC, JD and ADH received support from the University College
Academic Health Sciences Biomedical Research Centre. NSHD, AKG, RH and DK
were supported by the UK Medical Research Council (MC_UU_12018/1 and
MC_UU_12019/2).
Competing interests None declared.
Ethics approval The Central Manchester Local Research Ethics Committee—
(07/H1008/168) and the Scotland A Research Ethics Committee.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/
by/4.0/
REFERENCES
1 Redﬁeld MM, Jacobsen SJ, Burnett JC, et al. Burden of systolic and diastolic
ventricular. Intern Med 2003;289:194–202.
2 Halley CM, Houghtaling PL, Khalil MK, et al. Mortality rate in patients with diastolic
dysfunction and normal systolic function. Arch Intern Med 2011;171:1082–7.
3 Bella JN, Palmieri V, Roman MJ, et al. Mitral ratio of peak early to late diastolic
ﬁlling velocity as a predictor of mortality in middle-aged and elderly adults: the
Strong Heart Study. Circulation 2002;105:1928–33. http://www.ncbi.nlm.nih.gov/
pubmed/11997279 (accessed 18 Aug 2014).
4 Lee DS, Massaro JM, Wang TJ, et al. Antecedent blood pressure, body mass index,
and the risk of incident heart failure in later life. Hypertens 2007;50:869–76.
5 Allen N, Berry JD, Ning H, et al. Impact of blood pressure and blood pressure
change during middle age on the remaining lifetime risk for cardiovascular disease:
the cardiovascular lifetime risk pooling project. Circulation 2012;125:37–44.
6 Arnlov J, Lind L, Zethelius B, et al. Several factors associated with the insulin
resistance syndrome are predictors of left ventricular systolic dysfunction in a male
population after 20 years of follow-up. Am Heart J 2001;142:720–4.
7 Ghosh AK, Hardy RJ, Francis DP, et al. Midlife blood pressure change and left
ventricular mass and remodelling in older age in the 1946 British birth cohort
study. Eur Hear J 2014;35:3287–95.
8 Stafford M, Black S, Shah I, et al. Using a birth cohort to study ageing:
representativeness and response rates in The National Survey of Health and
Development. Eur J Ageing 2013;10:145–57.
9 Gray L, Lee I-M, Sesso HD, et al. Blood pressure in early adulthood, hypertension in
middle age, and future cardiovascular disease mortality: HAHS (Harvard Alumni
Health Study). J Am Coll Cardiol 2011;58:2396–403.
10 Stang A, Moebus S, Möhlenkamp S, et al. Algorithms for converting random-zero
to automated oscillometric blood pressure values, and vice versa. Am J Epidemiol
2006;164:85–94.
11 Kuh D, Pierce M, Adams J, et al. Cohort proﬁle: updating the cohort proﬁle for the
MRC National Survey of Health and Development: a new clinic-based data
collection for ageing research. Int J Epidemiol 2011;40:e1–9.
12 Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of
left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr
2009;22:107–33.
13 Fatema K, Bailey KR, Petty GW, et al. Increased left atrial volume index: potent
biomarker for ﬁrst-ever ischemic stroke. Mayo Clin Proc 2008;83:1107–15.
14 Keijzer-Veen MG, Euser AM, van et al. A regression model with unexplained
residuals was preferred in the analysis of the fetal origins of adult diseases
hypothesis. J Clin Epidemiol 2005;58:1320–4.
15 Wills AK, Lawlor DA, Matthews FE, et al. Life course trajectories of systolic blood
pressure using longitudinal data from eight UK cohorts. PLoS Med 2011;8:e1000440.
16 Arnlöv J, Lind L, Sundström J, et al. Insulin resistance, dietary fat intake and blood
pressure predict left ventricular diastolic function 20 years later. Nutr Metab
Cardiovasc Dis 2005;15:242–9.
17 Vasan RS, Benjamin EJ. Diastolic heart failure—no time to relax. N Engl J Med
2001;344:56–9.
18 Zile MR, Baicu CF, Bonnema DD. Diastolic heart failure: deﬁnitions and terminology.
Prog Cardiovasc Dis 2005;47:307–13.
Ghosh AK, et al. Heart 2016;0:1–8. doi:10.1136/heartjnl-2015-308836 7
Cardiac risk factors and prevention
group.bmj.com on July 26, 2016 - Published by http://heart.bmj.com/Downloaded from 
19 Gandhi SK, Powers JC, Nomeir AM, et al. The pathogenesis of acute pulmonary
edema associated with hypertension. N Engl J Med 2001;344:17–22.
20 Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80
years of age or older. N Engl J Med 2008;358:1887–98.
21 Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in
diastolic heart failure: the ancillary digitalis investigation group trial. Circulation
2006;114:397–403.
22 Solomon SD, Janardhanan R, Verma A, et al. Effect of angiotensin receptor blockade
and antihypertensive drugs on diastolic function in patients with hypertension and
diastolic dysfunction: a randomised trial. Lancet 2007;369:2079–87.
23 Tapp RJ, Sharp A, Stanton AV, et al. Differential effects of antihypertensive
treatment on left ventricular diastolic function: an ASCOT (Anglo-Scandinavian
Cardiac Outcomes Trial) substudy. J Am Coll Cardiol 2010;55:1875–81.
24 Barron AJ, Hughes AD, Sharp A, et al. Long-term antihypertensive treatment fails to
improve E/e0 despite regression of left ventricular mass: an Anglo-Scandinavian
cardiac outcomes trial substudy. Hypertension 2014;63:252–8.
25 Shah SJ, Gheorghiade M. Heart failure with preserved ejection fraction: treat now by
treating comorbidities. JAMA 2008;300:431–3.
26 Lehmann MV, Zeymer U, Dechend R, et al. Ambulatory blood pressure
monitoring: is it mandatory for blood pressure control in treated
hypertensive patients?: prospective observational study. Int J Cardiol
2013;168:2255–63.
27 Hill MN, Miller NH, Degeest S, et al. Adherence and persistence with taking
medication to control high blood pressure. J Am Soc Hypertens
2011;5:56–63.
28 Haider AW, Larson MG, Franklin SS, et al. Systolic blood pressure, diastolic blood
pressure, and pulse pressure as predictors of risk for congestive heart failure in the
Framingham Heart Study. Ann Intern Med 2003;138:10–16.
29 Franklin SS, Levy D. Aging, blood pressure, and heart failure: what are the
connections? Hypertension 2011;58:760–2.
30 Quiñones MA. Assessment of diastolic function. Prog Cardiovasc Dis
2005;47:340–55.
8 Ghosh AK, et al. Heart 2016;0:1–8. doi:10.1136/heartjnl-2015-308836
Cardiac risk factors and prevention
group.bmj.com on July 26, 2016 - Published by http://heart.bmj.com/Downloaded from 
pressure
diastolic dysfunction independently of blood 
Midlife blood pressure predicts future
Rebecca Hardy
Chaturvedi, Denis Pellerin, John Deanfield, Diana Kuh, Jamil Mayet and 
Arjun Kumar Ghosh, Alun David Hughes, Darrel Francis, Nishi
 published online April 7, 2016Heart 
 http://heart.bmj.com/content/early/2016/04/07/heartjnl-2015-308836





This article cites 30 articles, 6 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (8732)Drugs: cardiovascular system
 (2093)Echocardiography





To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on July 26, 2016 - Published by http://heart.bmj.com/Downloaded from 
